Clinical Trial Update: OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial OCTANE assesses adjuvant liposomal doxorubicin and carboplatin for early-stage triple-negative breast cancer; the study is currently active but no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Doxil (liposomal doxorubicin)

Snippet

Sponsor: Mridula George, MD | Conditions: Triple Negative Breast Cancer (TNBC) | Phase 2 | Status: ACTIVE_NOT_RECRUITING